{"disease":{"id":"advanced-non-squamous-nsclc","name":"Advanced Non-squamous NSCLC","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":1,"trial_count":0},"drugs":{"marketed":[{"drug_id":"pemetrexed-disodium","indication_name":"Locally Advanced or Metastatic Non-Squamous NSCLC - Initial Treatment with Cisplatin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PEMETREXED DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"sevabertinib","indication_name":"Locally advanced or metastatic non-squamous NSCLC with HER2 TKD mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SEVABERTINIB","company_name":"","drug_phase":"marketed","molecular_target":"HER2, EGFR","drug_class":"","quality_score":35,"revenue":null,"mechanism":"Sevabertinib inhibits HER2 and EGFR phosphorylation, blocking downstream signaling and cancer cell proliferation."},{"drug_id":"telisotuzumab","indication_name":"locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emrelis","generic_name":"TELISOTUZUMAB","company_name":"Abbvie Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Emrelis binds to the c-Met protein on cancer cells, blocking its growth-promoting signals."}],"pipeline":[{"drug_id":"bevacizumab-eu","indication_name":"Advanced Non-squamous NSCLC","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bevacizumab-EU","generic_name":"bevacizumab-eu","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 we","quality_score":0,"revenue":null,"mechanism":"15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 we"},{"drug_id":"pf-06439535-cn","indication_name":"Advanced non-squamous non-small-cell lung cancer (NSCLC)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06439535 (CN)","generic_name":"pf-06439535-cn","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Not publicly disclosed; presumed to be VEGF pathway or related angiogenic target based on clinical trial design","drug_class":"Selective pathway inhibitor; presumed anti-angiogenic agent","quality_score":null,"revenue":null,"mechanism":"Selective inhibitor blocking proteins that drive abnormal cell growth and division in cancer cells."}],"offLabel":[],"totalMarketed":3,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT06735391","title":"A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":516,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT00369070","title":"A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":186,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT03768037","title":"Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":106,"lead_sponsor_name":"Guangdong Association of Clinical Trials","has_results":false},{"nct_id":"NCT02133196","title":"T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04325698","title":"A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Pfizer","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}